0.70
-0.0052(-0.73%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.72 |
| Day High | 0.73 |
| Day Low | 0.69 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.69 |
| Volume | 227,331 |
| Average Volume | 328,292.1 |
| Market Cap | 22.96M |
| PE | -0.82 |
| EPS | -0.86 |
| Moving Average 50 Days | 0.88 |
| Moving Average 200 Days | 1.13 |
| Change | -0.01 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $58.74 as of August 18, 2025 at a share price of $0.705. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $350.7 as of August 18, 2025 at a share price of $0.705.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
GlobeNewswire Inc.
Aug 06, 2025 1:00 PM GMT
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility an
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
GlobeNewswire Inc.
Jul 01, 2025 1:00 PM GMT
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet nee
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
GlobeNewswire Inc.
Jun 25, 2025 1:00 PM GMT
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women--ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a